(Rac) -Minzasolmin
(Rac) -Minzasolmin ((Rac) -UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac) -Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac) -Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac) -Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) [1].
Product Specifications
CAS Number
1802518-63-3
Product Name Alternative
(Rac) -UCB0599; NPT200-11
UNSPSC
12352005
Target
α-synuclein
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/rac-minzasolmin.html
Purity
99.87
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CN=C(N2CCN(CC2)C)S1)NC(CCCC)CC3=CNC4=CC=CC=C34
Molecular Formula
C23H31N5OS
Molecular Weight
425.59
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
α-synuclein Aggregation
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MART-1 / Melan-A (M2-7C10), CF568 conjugate, 0.1mg/mL
CD45RO (190-2F2.5), CF647 conjugate, 0.1mg/mL
CD63 (MX-49.129.5), CF555 conjugate, 0.1mg/mL
